Destiny Pharma (AIM: DEST) has entered into a collaboration in COVID-19 with fellow UK-based biotech SporeGen.
The project is aimed at developing the latter’s SPOR-COV product as a novel, preventive treatment for COVID-19.
SporeGen is working exclusively on the Bacillus bacteria and its applications, whereas Destiny is focused on the development of novel, hospital infection prevention treatments that address the global challenge of antimicrobial resistance (AMR).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze